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The incidence of Achilles tendon ruptures is rising among active
individuals regardless of age. Although operative reconstruction is
a standard approach to rupture care, it is accompanied by a non-
trivial risk of complications.11 Overall, open repair is specially
indicated for active people since it re-establishes ﬁber continuity,
reducing re-rupture risk and improving long-term functional
outcome.16When post-surgical complications arise, their manage-
ment is demanding, particularly in extensively diseased tendons.
Although relatively infrequent, deep infection along with tendon
necrosis can be a devastating complication requiring repeated
surgery. Determining optimal treatment for this entity is a
signiﬁcant challenge to the orthopaedic surgeon.14,17
The emergence of platelet-rich technologies has created new
therapeutic opportunities by combining an understanding of the
biology of tendon injury and repair with surgical principles.6,22 Our
group is investigating the use of the versatile autologous
preparation termed preparation rich in growth factors (PRGF) in
different medical conditions.3,21 PRGF has been shown to enhance
and accelerate soft tissue repair in cutaneous ulcers,6 to improve
bone repair in oral implantology7 and non-unions in orthopae-
dics,23 to ameliorate intra-articular conditions in select osteoar-
thritis (OA) patients22 and to enhance soft tissue healing and
remodeling in anterior cruciate ligament (ACL) reconstructive
surgery as well as ruptured Achilles tendons in professional
athletes.20,23
This report describes PRGF-assisted management of major
complications in two recreational athletes after initial surgical* Corresponding author. Tel.: +34 945 297030; fax: +34 945 297031.
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doi:10.1016/j.injury.2008.09.017management of acute Achilles tendon rupture. To our knowledge,
this is the ﬁrst article reporting the use of platelet-rich prepara-
tions in severe complications after primary Achilles repair. The
biosafety, versatility and ease of preparation of platelet-based
formulations in combination with our promising clinical results
moved us to share our experience in hopes of inspiring awareness
and further investigation of this novel therapeutic option.
2. Patients and methods
2.1. Case presentation
2.1.1. Case #1
A 52-year-old male recreational athlete with a history of
Achilles tendinopathy and acute Achilles rupture at the calcaneous
insertion was referred to our institution post-surgical therapy. He
reported difﬁculty walking, impairment of ankle plantar ﬂexion
and sharp pain at the posterior aspect of his left ankle to superﬁcial
calcaneus palpation. Clinical evaluation disclosed a wound ﬁstula
in the distal region of the surgical scar, and a defect was palpated
around the prominent superior tuberosity of the calcaneous.
Complementary axial computerised tomography, magnetic reso-
nance imaging and histology conﬁrmed active osteomyelitis,
interstitial tears and the presence of necrotic areas all along the
entire length of the Achilles tendon (Fig. 1A). Microbial cultures
ascertained the presence of Klebsiella both in tendon and
calcaneus bone, prompting intravenous ciproﬂoxacin for 1 week
and oral ciproﬂoxacin treatment for 2 more weeks.
2.1.2. Case #2
A 62-year-old male mountain medicine physician and profes-
sional mountaineer with asymptomatic degenerative tendino-
pathy (Fig. 1B) who had been previously operated on at our
Fig. 1. Severe Achilles tendon disorders in case #1 (A) and case #2 (B).
Fig. 2. Extensive tissue removal leaving 8–10-cm tendon gaps.
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months later with a persistent infected ﬁstula, possibly caused by
an intolerance to the PDS suture (polydioxanone, Johnson&John-
son, Brussels, Belgium) used in the previous end-to-end repair. As
microbial cultures identiﬁed the presence of Streptococcus
agalacticae, oral cloxacilin three times a day was prescribed. After
3 weeks, the ﬁstula was still active and required surgical
debridement.
3. Treatment
A two-stage operation was planned for both cases. The ﬁrst
stage involved surgical debridement and use of PRGF technology as
described below. Because the post-debridement defect between
tendon and healthy tissue was larger than 8–10 cm, the second
planned stage involved graft augmentation in both cases. In the
end, graft augmentation was only performed in case #1.
3.1. PRGF preparation
For the preparation of PRGF, 80 ml of peripheral venous blood
was drawn from each patient into 9 ml tubes containing 3.8% (w/v)
sodium citrate. PRGF was prepared by centrifugation at 640 g for
8 min at room temperature (BTI System, Vitoria, Spain). In order to
prepare the autologousﬁbrinmembrane, 8–12 ml of plasma located
at the top of the tubes was transferred to a glass bowl. After adding
calcium chloride, the mixture was incubated for 30–40 min,
allowing for the formation of a biocompatible ﬁbrin membrane
that promotes full epithelialisation of soft tissues. The 2 ml plasma
fraction located just above the sedimented red cells, but not
including the buffy coat, was collected in another tube. This fraction
was injected in liquid form after activation or clotted ex vivo and
immediately transferred to the bone defect as shown below.
3.2. Surgical debridement and PRGF application
3.2.1. Surgical debridement
In both cases, surgery involved extensive removal of the
degenerated area.
In case #1, a single incisionwasmade along the Achilles tendon,
exposing the retrocalcaneal bursa and fat pad, which werecompletely excised. We found a surgical anchor around the
calcaneous insertion that had been used for distal attachment
during primary repair. Debridement included resection of this
anchor as well as the necrotic distal tendon insertion onto the
calcaneus and 8 cm of tendon extending proximally from tendon
insertion (Fig. 2A).
In case #2, a 15 cm incision was made in line with the
previous incision over the posterior aspect of the Achilles tendon.
The tendon showed extensive degenerative changes, and the
mucoid area was sharply dissected and removed (Fig. 2B). After
debridement, only 2–3 cm of the distal tendon end was left,
creating a tendon defect greater than 10 cm. A construct was
made, approximating by traction the proximal thickened
paratenon, fashioned into a tube and sutured in under strain
to the 2–3 cm remaining distal tendon-end using FiberWire1
(Arthrex Inc., Naples, FL, USA). At the end of surgery, a 1–2 cm
gap persisted.
3.2.2. PRGF application
After cleaning the degenerated area, the different formulations
of PRGF were applied as follows:(i) In both cases, 3 ml of the activated liquid preparation was
injected in the distal and/or proximal stump (Fig. 3A).(ii) In case #1 PRGF, scaffolds were applied to entirely ﬁll the
tendon gap and the calcaneus tubercle defect.(iii) In case #2, the paratenon construct was abundantly injected
with PRGF, and the remaining 1–2 cm gap was ﬁlled with a
PRGF clot.(iv) In both cases, before closing the skin, the elastic PRGF
membrane formed ‘‘ex vivo’’ was used to cover the treated
areas as shown in Fig. 3B.Patients were given prophylactic antibiotics and anti-throm-
botics after surgery. A below-the-knee dorsal plaster splint was
applied with the ankle in the equinus position. Patients were
allowed to walk with elbow crutches without weight-bearing.
Fig. 3. PRGF inﬁltration within the proximal stump (A) and the application of an
autologous ﬁbrin membrane covering the entire area (B).
Fig. 5. PRGF-assisted grafting procedure: PRGF was applied at the donor site after
harvesting the semitendinosus (A); activated PRGF is injected within the graft (B)
and the reconstructed tendon (C); and the affected area is covered with the ﬁbrin
scaffold (D).
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Initially, graft augmentation was planned for both patients. In
case #1, tendon autograft was scheduled and carried out 3 weeks
later. In case #2 the patient experienced good clinical recovery and
had promising ultrasound scans during follow-up. As such, graft
augmentation was delayed and eventually deemed unnecessary.
3.3.1. Case #1
Upon re-opening, we found interposed tissue bridging the gap
all along the length of the tendon defect (Fig. 4). Surprisingly,
pulling the proximal tendon-end induced plantar ﬂexion. To
further strengthen this tissue, 6 ml of activated PRGF was injected
into the newly formed tissue. An autologous semi-tendinosus
tendon was used to bridge the large Achilles defect to further
reinforce and augment the repair site. To harvest the tendon, we
made an incision over the pes anserinus and placed a PRGF scaffold
at the donor site to helpwith healing (Fig. 5A). Before transplanting
this tendon, small volumes of liquid PRGFwere injected among theFig. 4. The repair tissue formed 3 weeks after debridement and PRGF application in
case #1.tendon ﬁbres to activate tendon cells as previously described by
Sanchez et al.21 (Fig. 5B). The graft was then anchored to the
calcaneus bone by drilling a bone tunnel and suturing to the
proximal stump of the tendon. A number-0 Vycril locking suture
was run along the underlying newly formed tissue to make a very
solid construct (Fig. 5C). After closing the paratenon but before
closing the overlying skin, the affected area was covered with a
ﬁbrin membrane (Fig. 5D).
4. Outcome and follow-up
4.1. Case #1
1 week after tendon grafting and PRGF application, patient #1
felt able to perform active ankle ﬂexion-extension. At this point,
assisted physical therapy was begun. The patient was instructed to
do a small series of dorsal/plantar ﬂexion exercises. A gradual
increase of ankle angulations during ﬂexion was achieved. The
range of motion of the ankle was 88/108 dorsal/plantar by the end
of the ﬁrst week and 158/238 by the fourth week. At this point,
partial weight bearing (50% of his weight) was allowed and
increased to 70% by the sixth week. Full weight-bearing was
achieved by the eighth week, at which point the range of motion
was 208/588. Fifteen minutes of stationary bicycling and 1500 m
progressive marching were included in physical therapy by week
10 with progressively increasing duration and intensity. The
patient resumed football training activities byweek 14. At the time
Fig. 6. Functional result of case #2 at 1 year.
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training and competing without any recurrence of symptoms.
4.2. Case #2
The plaster cast was removed after 14 days, and physical
therapy was begun. This was followed by 4 weeks of partial
weight-bearing as the patient felt able, using elbow crutches and a
heel lift with the foot strapped into the equinus position using an
adhesive bandage. After 6 weeks, the patient felt able to ambulate.
Full weight-bearing and a complete range of motion was achieved
by the end of the 10th week. The patient’s functional result 1-year
post-treatment is shown in Fig. 6. The patient resumed normal
mountain climbing activities after 7 months without any
recurrence of symptoms. Notably, 10 months after surgery, the
patient was able to attempt climbing a peak over 7000-m high
(Aconcagua, Argentina). MR imaging (Fig. 7) shows in detail the
condition of the tendon at the time of writing, 5 years after PRGF-
assisted surgical debridement. Although imaging abnormalities
were found, the Achilles tendon has been functional and
asymptomatic during this period. The healed Achilles tendon
shows a thickened appearance and areas of increased signal
intensity. The latter may be associated with some persistent age-
dependent degenerative changes.
5. Discussion
We report PRGF-assisted management of major post-operative
complications such as infection and Achilles tendon necrosis in
two recreational athletes. The two cases were challenging due to
the critical length of the tendon defects (>8–10 cm) and theFig. 7. Sagital T1-weighted fat-suppressed (A) and proton density fat saturation (PDFS)
consistent with background mucoid degeneration. Axial T1-weighted fat-suppressed (C)
speckled appearance consistent with mucoid degeneration and loss of normal concavedetached bone-tendon insertion in case #1. We used a two-step
approach to manage these patients: (1) a surgical toilette to
remove degenerated tissue and (2) a tendon augmentation to
strength the tissue to deal with the large tensile forces generated
by muscles. PRGF was used in both stages.
As the understanding of tendon biology and repair mechanisms
improves, we have begun to better understand the molecular
mechanisms underlying the beneﬁt of PRGF.9,10,12,13 In the surgical
toilette, the PRGF scaffold served to establish the physical(B) MR images show thickening of the Achilles tendon. Internal signals can be seen
and PDFS (D) proximal, mid-substance (E and F) and distal (G and H) images show
anterior margin.
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tendon insertion, providing a structure for cell migration and
proliferation. This is thought to facilitate the formation of tissue
with dense collagen ﬁbres as well as proliferating ﬁbroblasts and
vessels.18 By covering the area with a PRGF membrane, we likely
facilitated an extrinsic repairing mechanism by which ﬁbroblasts
couldmove easily from the peripheral paratenon or external tissue
sources to the healing site. This emphasises the importance of
structures in close communication with the Achilles tendon,
speciﬁcally the paratenon, skin barrier and subcutis.15
In addition to providing a ﬁbrin scaffold, PRGF allows delivery of
the necessary signalling molecules critical to a successful repair.1,8
Platelets embedded in the scaffold secrete a large pool of proteins
and factors including PDGF, TGF-b, VEGF, IGF-I, and HGF, among
others to the localmilieu.19 In our previousworkwe have observed
that this pool of released growth factors from PRGF increases the
proliferation of human tendon cells and stimulates them to
produce type I collagen and angiogenic factors such as HGF and
VEGF.2 The latter are critical for neovascularisation and main-
tenance of vasculature present in the endotenon and epitenon. HGF
is a potent anti-ﬁbrotic agent that could reduce scar formation
around tendons.5 Additional experiments conducted in a sheep
model conﬁrmed increased cellularity and vascularity as well as
the absence of ﬁbrosis after PRGF injection within Achilles
tendons.4 Other authors have shown that, during the initial repair
process, growth factors such as IGF-I stimulate the migration and
proliferation of ﬁbroblasts to the wound site.24,25 Based on these
experimental results, we proposed a novel approach to create fully
integrated bioactive grafts by injecting PRGF into the semi-
tendinosus graft. We believed that this approach would add to the
scaffold structure the necessary biological cues for cell migration,
proliferation, angiogenesis and remodelling to result in better
patient outcomes.
As research into tendon disorders continues, additional novel
biological therapies are being translated into the clinic and
operating room. When evaluating different therapeutic options,
clinicians must weigh a treatment’s versatility, biocompatibility
and efﬁcacy. PRGF application in combination with surgery
represents an option that may meet these criteria for treatment
of major complications from Achilles tendon rupture and repair.
With its use, we were able to resolve major tendon problems that
were causing marked morbidity and functional impairment.
6. Conclusions
Platelet-rich preparations fall into the novel biological arma-
mentarium and offer new therapeutic opportunities in post-
surgical complications of Achilles tendon rupture. This report
describes the use of PRGF as an aid in healing after debridement
and augmentation procedures. Our results indicate that a PRGF-
assisted regenerative technique may be suitable in the manage-
ment severe complications in Achilles tendon conditions.
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